- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 455/08 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberineAlkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberineAlkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems having an isoquinolyl-1, a substituted isoquinolyl-1 or an alkylenedioxyisoquinolyl-1 radical linked through only one carbon atom, attached in position 2, e.g. emetine
Patent holdings for IPC class C07D 455/08
Total number of patents in this class: 8
10-year publication summary
|
3
|
1
|
1
|
0
|
0
|
1
|
0
|
0
|
1
|
0
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Howard University | 198 |
3 |
| Acer Therapeutics Inc. | 31 |
1 |
| Auspex Pharmaceuticals, Inc. | 143 |
1 |
| Chengdu Herbpurify Co., Ltd. | 1 |
1 |
| Crystal Pharmaceutical (Suzhou) Co., Ltd. | 122 |
1 |
| Shanghai Shijiang Biotechnology Co., Ltd | 17 |
1 |
| Other owners | 0 |